Saturday, July 30, 2016

Oramed posts positive oral insulin data

Oramed posts positive oral insulin data

July 28, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically significant lowering of glucose relative to placebo across several endpoints. “ORMD-0801 was safe and efficacious in reducing blood glucose endpoints with a promising clinically […]

Feltl upgrades Novadaq to strong buy

Feltl upgrades Novadaq to strong buy

July 28, 2016 by · Leave a Comment 

Tweet Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales business. Analyst Ben Haynor maintained his price target of $15 on Novadaq. The stock was quoted $10.13, up $1.30, at mid-day Thursday. “At […]

Corey Davis joins HCW’s research team

Corey Davis joins HCW’s research team

July 28, 2016 by · Leave a Comment 

Tweet Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals. Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending most of those years at JP Morgan and Jefferies. His therapeutic areas of focus include CNS-related disorders, such as multiple sclerosis, epilepsy, depression, bipolar disorder, pain […]

ProMIS releases clinical results at Alzheimer’s conference

ProMIS releases clinical results at Alzheimer’s conference

July 28, 2016 by · Leave a Comment 

Tweet ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto. “Our results presented at the AAIC meeting indicate that multiple monoclonal antibodies (mAbs) directed against five novel AD targets are viable therapeutic candidates, as they showed selective binding to the oligomeric forms of […]

Novadaq Q2 revenue climbs 34%

Novadaq Q2 revenue climbs 34%

July 27, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago. Total direct sales in the latest quarter increased by $4.4-million, or 37%, and total partnered/international sales rose by $600,000, or 21%, compared with the same period last year. The company estimates that the number […]

Anavex reports Phase 2a efficacy data in AD

Anavex reports Phase 2a efficacy data in AD

July 27, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto. Overall, efficacy results demonstrate what appears to be a converging and consistent response for all quantitative endpoints through 31 weeks, including cognitive and functional […]

BTIG downgrades NeoGenomics to neutral

BTIG downgrades NeoGenomics to neutral

July 27, 2016 by · Leave a Comment 

Tweet BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday. Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business continues to trend well and with more clarity around Medicare in 2017, we think downside risk is fairly modest,” he said. “[NeoGenomics’] shares […]

Avivagen, UNAHCO register OxC-beta in Philippines

Avivagen, UNAHCO register OxC-beta in Philippines

July 27, 2016 by · Leave a Comment 

Tweet Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines. UNAHCO is a feed and veterinary unit of Unilab, the largest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet […]

Oramed names Dr. Roy Eldor as CMD

Oramed names Dr. Roy Eldor as CMD

July 26, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director. “We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a Phase 3 trial for our oral insulin capsule, ORMD-0801,” CEO, Nadav Kidron, said in a statement. Dr. […]

Tandem expands pediatric indication of insulin pump

Tandem expands pediatric indication of insulin pump

July 26, 2016 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the […]

Next Page »

Email Newsletters with Constant Contact
Google+